This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2012 Jul 18;308(3):290-1.

doi: 10.1001/jama.2012.8327.

Evaluating the potential benefit of interferon treatment in multiple sclerosis

Tobias Derfuss, Ludwig Kappos

PMID: 22797647
DOI: 10.1001/jama.2012.8327

Editorial

Evaluating the potential benefit of interferon treatment in multiple sclerosis

Tobias Derfuss et al. JAMA. 2012.

. 2012 Jul 18;308(3):290-1.

doi: 10.1001/jama.2012.8327.

Authors

Tobias Derfuss, Ludwig Kappos

PMID: 22797647
DOI: 10.1001/jama.2012.8327

No abstract available

PubMed Disclaimer

Comment on

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H. Shirani A, et al. JAMA. 2012 Jul 18;308(3):247-56. doi: 10.1001/jama.2012.7625. JAMA. 2012. PMID: 22797642

Similar articles

Treatment with interferon beta for multiple sclerosis.
Goodin DS, Reder AT, Cutter G. Goodin DS, et al. JAMA. 2012 Oct 24;308(16):1627; author reply 1627-8. doi: 10.1001/jama.2012.13570. JAMA. 2012. PMID: 23093155 No abstract available.
[Does interferon beta slow the progression of multiple sclerosis? Long-term effect of IFN-β on progression of physical disability is still not proven].
Hohlfeld R. Hohlfeld R. Dtsch Med Wochenschr. 2012 Oct;137(41):2088. doi: 10.1055/s-0032-1327081. Epub 2012 Oct 2. Dtsch Med Wochenschr. 2012. PMID: 23033165 German. No abstract available.
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H. Shirani A, et al. JAMA. 2012 Jul 18;308(3):247-56. doi: 10.1001/jama.2012.7625. JAMA. 2012. PMID: 22797642
Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
Farrell RA, Giovannoni G. Farrell RA, et al. Mult Scler. 2007 Jun;13(5):567-77. doi: 10.1177/1352458506073522. Epub 2007 Feb 16. Mult Scler. 2007. PMID: 17548434 Review.
The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.
Kieseier BC. Kieseier BC. Expert Rev Neurother. 2014 Jan;14(1):105-20. doi: 10.1586/14737175.2014.869478. Expert Rev Neurother. 2014. PMID: 24417500 Review.

See all similar articles

Cited by

Advances in the treatment of relapsing-remitting multiple sclerosis: the role of pegylated interferon β-1a.
Furber KL, Van Agten M, Evans C, Haddadi A, Doucette JR, Nazarali AJ. Furber KL, et al. Degener Neurol Neuromuscul Dis. 2017 Mar 24;7:47-60. doi: 10.2147/DNND.S71986. eCollection 2017. Degener Neurol Neuromuscul Dis. 2017. PMID: 30050377 Free PMC article. Review.
["Time is brain" in relapsing remitting multiple sclerosis. Current treatment concepts in immunotherapy].
Linker R, Kallmann BA, Kleinschnitz C, Rieckmann P, Mäurer M, Schwab S. Linker R, et al. Nervenarzt. 2015 Dec;86(12):1528-37. doi: 10.1007/s00115-015-4439-x. Nervenarzt. 2015. PMID: 26556094 Review. German.
Estimating typical multiple sclerosis disability progression speed from clinical observations.
Brown MG, Asbridge M, Hicks V, Kirby S, Murray TJ, Andreou P, Lin D. Brown MG, et al. PLoS One. 2014 Oct 17;9(10):e105123. doi: 10.1371/journal.pone.0105123. eCollection 2014. PLoS One. 2014. PMID: 25329469 Free PMC article.
Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort.
Karim ME, Gustafson P, Petkau J, Zhao Y, Shirani A, Kingwell E, Evans C, van der Kop M, Oger J, Tremlett H. Karim ME, et al. Am J Epidemiol. 2014 Jul 15;180(2):160-71. doi: 10.1093/aje/kwu125. Epub 2014 Jun 17. Am J Epidemiol. 2014. PMID: 24939980 Free PMC article.
Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects.
Rommer PS, Stüve O. Rommer PS, et al. Curr Treat Options Neurol. 2013 Jun;15(3):241-58. doi: 10.1007/s11940-013-0233-x. Curr Treat Options Neurol. 2013. PMID: 23609781

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information